Cor Vasa 2008, 50(4):177-182 | DOI: 10.33678/cor.2008.058

Managing acute heart failure.

Jindřich Špinar1, Ivan Málek2
1 Interní kardiologická klinika, Fakultní nemocnice Brno-Bohunice a Lékařská fakulta Masarykovy univerzity, Brno
2 Klinika kardiologie, Institut klinické a experimentální medicíny, Praha, Česká republika

Acute heart failure is a condition associated with high mortality rates and one difficult to treat. As no large mortality studies demonstrating an effect of treatment on survival have been reported, treatment is based on experience and is largely empirical. Factors central to the decision regarding the therapy to be used include the patient s clinical condition and the cause of heart failure. The main class of drugs used in pharmacotherapy are diuretics, with vasodilators used in patients with a hypertensive response while, conversely, positive inotropic agents are administered to those with hypotension.
All these modes of action are combined in levosimedan, a calcium sensitizer. Drug therapy is usually complemented with mechanical ventilation, and/or methods of elimination. Some patients require surgery, and various support systems have emerged recently, which hold promise for the most critically ill.

Keywords: Acute heart failure; Diuretics; Vasodilators; Inotropic agents; Levosimendan

Published: April 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Špinar J, Málek I. Managing acute heart failure. Cor Vasa. 2008;50(4):177-182. doi: 10.33678/cor.2008.058.
Download citation

References

  1. Málek F, Ignaszewski A. Nové léky pro terapii pokročilého srdečního selhání. Cor Vasa 2004;46:221-5.
  2. Nieminen MS, Boehm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J 2005;26:383-416.
  3. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:1115-40. Go to original source... Go to PubMed...
  4. Špinar J, Hradec J, Lupínek P, a spol. Doporučení pro diagnostiku a léčbu chronického srdečního selhání - guidelines ČKS 2006. Cor et Vasa 2007;49:K5-K34.
  5. Špinar J, Janský P, Kettner J, Málek I. Doporučení pro diagnostiku a léčbu akutního srdečního selhání. Cor Vasa 2006;48:K3-K31.
  6. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. New Engl J Med 2001;345:1359-67. Go to original source... Go to PubMed...
  7. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000;102:203-10. Go to original source...
  8. Bellomo R. Continuous haemofiltration in the intensive care unit. Crit Care 2000;4:339-45. Go to original source... Go to PubMed...
  9. Cotter G, Weissgarten J, Metzkor E, et al. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther 1997;62:187-93. Go to original source... Go to PubMed...
  10. Neuberg GW, Miller AB, O'Connor CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31-8. Go to original source... Go to PubMed...
  11. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998; 351:389-93. Go to original source... Go to PubMed...
  12. Katz AM. Potential deleterious effect of inotropic agents in the therapy of chronic heart failure. Circulation 1986;73:III84-III90.
  13. Schulz R, Rose J, Martin C, et al. Development of short-term myocardial hibernation. Its limitation by the severity of ischemia and inotropic stimulation. Circulation 1993;88:684-95. Go to original source...
  14. Colucci WS, Denniss AR, Leatherman GF, et al. Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition. J Clin Invest 1988;81:1103-10. Go to original source... Go to PubMed...
  15. Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. New Engl J Med 1986;314:290-9. Go to original source... Go to PubMed...
  16. Colucci WS, Wright RF, Jaski BE, et al. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. Circulation 1986;73:III175-III183.
  17. ANZICS Clinical Trials Group. Low-dose dopamine in patients with early renal dysfunction: a placebo controlled randomised trial. Lancet 2000;356:2139-43. Go to original source...
  18. Keung EC, Siskind SJ, Sonneblick EH, et al. Dobutamine therapy in acute myocardial infarction. JAMA 1981;245:144-6. Go to original source... Go to PubMed...
  19. Lowes BD, Tsvetkova T, Eichhorn EJ, et al. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol 2001;81:141-9. Go to original source...
  20. Thackray S, Easthaugh J, Freemantle N, et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure - a meta-regression analysis. Eur J Heart Fail 2002;4:515-29. Go to original source... Go to PubMed...
  21. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999;138:78-86. Go to original source... Go to PubMed...
  22. Silver MA, Horton DP, Ghali JK, et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002;39:798-803. Go to original source...
  23. Cuffe MS, Califf RM, Adams KF Jr., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287:1541-7. Go to original source... Go to PubMed...
  24. Metra M, Nodari S, D'Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002;40:1248-58. Go to original source...
  25. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871-8. Go to original source...
  26. Janoušek S. Levosimendan na postupu v léčbě srdečního selhání. Cor Vasa 2004;46:597-600.
  27. Cleland JGF, McGowan J. Levosimendan: a new era for inodilator therapy for heart failure? Curr Opin Cardiol 2002;17:257-65. Go to original source... Go to PubMed...
  28. Cleland JGF, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative metaanalyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT,CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004;6:501-8. Go to original source... Go to PubMed...
  29. Delle Karth G, Buberl A, Geppert A, et al. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand 2003;47:1251-6. Go to original source... Go to PubMed...
  30. Špinar J, Vítovec J. Levosimendan mění indikace i dávkování. Cor Vasa 2007;49:108-10.
  31. Follath F, Clelenad JGF, Just H, et al. Efficacy and safety of intravenous levosimendan in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202. Go to original source...
  32. Moiseyev VS, Poder D, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer levosimendan, in patients with left ventricular failure due to an acute myocardial infarcton. Eur Heart J 2002;23:1422-32. Go to original source...
  33. Widimský P, Janoušek S, Vojáček J. Doporučení pro diagnostiku a léčbu akutního infarktu myokardu (Q-typ//s elevacemi ST//s raménkovým blokem). Cor Vasa 2002;44:K123-K143.
  34. Samama MM, Cohen AT, Darmon JY, et al. A comparsion of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. New Engl J Med 1999;341:793-800. Go to original source... Go to PubMed...
  35. Al-Khadra AS, Salem DN, Rand WM, et al. Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol 1998;31:749-53. Go to original source...
  36. Lee G, DeMaria AN, Amsterdam EA, et al. Comparative effects of morphine, meperidine and pentazocine on cardiocirculatory dynamics in patients with acute myocardial infarction. Am J Med 1976;60:949-55. Go to original source... Go to PubMed...
  37. Wilson J, Woods I, Fawcett J, et al. Reducing the risk of major elective surgery: randomised controlled trial of preoperative optimisation of oxygen delivery. Br Med J 1999;318:1099-103. Go to original source... Go to PubMed...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.